NVS241220P145000
- 0.00
- 0.000.00%
Novartis AG Newsroom
Erste Group Downgrades Novartis AG(NVS.US) to Hold Rating
Express News | Us CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada
Novartis Currently Down Seven Consecutive Days, on Track for Longest Losing Streak Since May 2023 -- Data Talk
Novartis Pharma, Ratio Therapeutics Collaborate to Develop Cancer Treatment Candidate
Ratio Therapeutics Enters License And Collaboration Agreement With Novartis For SSTR2-Targeting Radiotherapeutic Candidate; Under The Terms Of The Agreement, Ratio Will Receive Combined Upfront And Potential Milestone Payments Up To $745M
US Manufacturing Index Rises To 43, Highest Since 2020
Top Gap Ups and Downs on Friday: NVO, HSBC, AMAT and More
Novartis Says Talks for Prostate Cancer Treatment Fail to Secure Deal
Express News | Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
UBS Sticks to Their Buy Rating for Novartis AG (NOVN)
Novartis (NVS.US)'s Lutetium [177Lu] Lu 肽-617 market application accepted by the CDE.
Nuclear medicine represented by radiopharmaceutical therapy is an area where Novartis has heavily invested.
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Express News | Schrodinger Shares Are Trading Higher After the Company Raised Its FY24 Software Revenue Growth Guidance. Additioanlly, the Company Announced a Research Collaboration and License Agreement With Novartis to Advance Multiple Development Candidates
Schrödinger's Stock Pops as It Enters Collaboration Pact With Novartis Worth up to $2.5 Billion
Schrödinger Announced Research Collaboration And License Agreement With Novartis To Advance Multiple Development Candidates Into Novartis's Portfolio For Further Development, Schrödinger To Receive $150M Upfront And Eligible To Receive Up To...
Schrödinger Reports Third Quarter 2024 Financial Results
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
J.P. Morgan Remains a Hold on Novartis AG (NOVN)
Novartis AG Falls Wednesday
Tango Stock Plunges 28% Amid Pipeline Updates, Q3 Earnings Report